Home|Journals|Articles by Year|Audio Abstracts
 

Original Article

J App Pharm Sci. 2018; 8(8): 107-115


Novel synthetic analogues of Fluoxetine as potent and selective anti-TB agents

M. Murali Krishna Kumar, K. Madhavi, T. Mohan, K. Purna Nagasree, G. P. V. Sangeeta.




Abstract

We have recently identified potent anti TB activity in several CNS drugs. Most prominently, the phenothiazine antipsychotics (Thioridazine-MIC 3.125μg/mL) and anti-depressant drugs (sertraline-MIC 1.6μg/mL) have shown anti TB activity against Mycobacterium tuberculosis H37Rv. In continuation, we have synthesized a series of 1-(3-aryloxy-3-phenylpropyl) amine analogues of fluoxetine with a view to optimize its anti TB activity. Identities of the synthesized compounds were confirmed on the basis of FTIR, 1H NMR and mass spectral analysis. Further, all synthesized compounds and intermediates were screened for antimicrobial activity using serial dilution method. Antitubercular activities of these compounds were performed by using Microplate Alamar Blue Assay (MABA) method. Among the synthesized compounds, 1-(3-(4-fluorophenoxy)-3-phenylpropyl)piperidine(AM3e) has shown highest anti TB activity (MIC 1.6μg/mL) against MtbH37Rv and is free from antibacterial/antifungal activity (MIC >100μg/mL).

Key words: Acetophenone mannich bases, fluoxetine, antitubercular activity, drug repurposing






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.